Abstract Background: Medicinal plants have been a major source of therapeutic agents from ancient times to cure diseases. The evaluation of rich heritage of traditional medicine is essential. The bark of Terminalia arjuna is rich in polyphenols (60-70%) including flavonoids and tannins.
28.00%, and 36.88% respectively at the highest dose (TA 4 ) for the three different durations viz., 24, 48 and 72 h. Similarly the number of sister chromatid exchanges got reduced from a higher level of 15.00 ± 1.40 per cell to 7.70 ± 0.50 per cell with S 9 mix at 48 h of treatment. The replication index was enhanced from 1.33 to 1.55 in vitro. Similar trends were noticed in the in vivo experiments i.e., effective reductions in clastogeny ranging from 15.22% to 54.82% from the mutagen treated positive control and the total frequencies in aberrant cells got reduced from 429 due to AFB1 to 141 due to 5th concentration of Terminalia extracts at 32 h of exposure.
Conclusion: The ameliorating potential of Terminalia extracts was dose and time dependant.
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Introduction
The evaluation of the rich heritage of traditional medicine is an important task for pharmacologist. In this regard the Terminalia arjuna is one such plant, which is distributed throughout the Indian Peninsula and is abundantly found in Sub-Himalayan tract. In the Indian system of medicine, the bark of the plant is used for curing ulcers, leucorrhoea, diabetes, tumor, asthma and inflammation etc. [1] . It was earlier observed that tannins and flavonoids are responsible for their anticancer properties [2] . There may be some chemical agents present in plants that may act as anticarcinogen or antimutagen by blocking or trapping ultimate carcinogen electrophile in a nucleophilic chemical reaction to form innocuous products. It was shown that the bark of T. arjuna is rich in polyphenols (60-70%) including flavonoids, tannins and triterpenoids [3] . These constituents are mainly responsible for anticancer activity. According to Sumitra et al. [4] the constituents of T. arjuna such as arjunolic acid and ascorbic acid arrest a decrease in antioxidant system, alpha tocopherol reduced glutathione as well as lipid peroxide and protect the heart from damage caused due to myocardial necrosis which is induced by isoproterenol. In a study by Devi et al. [5] the gastro-protective properties of T. arjuna in Diclofenac sodium induced gastric ulcer in rats due to its scavenging action of free radical and cyto-protective nature. The T. arjuna preparation at 50 mg/kg of body weight of dose, significantly decreases the higher level of the antioxidants produced by carbon tetrachloride induced oxidative stress and increases the reduced glutathione content. It also decreases the lipid peroxidation and its products [6] . A triterpenoid saponin, arjunin isolated from the arjuna plant ameliorates arsenic induced cyto-toxicity in isolated murine hepatocytes via normalizing the altered enzymatic and non-enzymatic levels [7] . In another study, the anti-inflammatory and immunomodulatory activities of the bark in mice and rats were also reported [8] . The aim of the present investigation is to highlight the anticarcinogenic and antimutagenic potential of T. arjuna extracts in vitro and in vivo.
Materials and methods

Aflatoxins B 1
Aflatoxins are produced by Aspergillus flavus and A. parasiticus at any time during growth and post harvest storage of a number of foodstuffs and the levels of contamination are enhanced under poor food harvesting and storage practices [9, 10] that lead to aflatoxin B 1 exposure to human. The major concern with respect to human health derives from the high potency of aflatoxins to produce cancer in laboratory animals and correlates with the evidence that AFB1 is a liver carcinogen in human populations [11] [12] [13] .
Terminalia arjuna
The name Terminalia is derived from latin 'Teminalis' due to terminal crowding of the leaves in many species of the genus Terminalia [14] . It belongs to the family Combretaceae. It is a large deciduous tree with buttressed roots, and reaches up to 60-70 feet. Stem is covered with white-gray bark which changes its color to pink according to season and age of the bark, and flakes off in large flat pieces from the trunk [1] .
Extract preparation
The sun dried bark of T. arjuna was brought to the laboratory and powdered and extracted in water (1:8, after passing through 80 mesh size) by boiling (4 h). The extracts were subsequently filtered through muslin cloth and the filtrate was spray dried. For preparation of water solution of T. arjuna extracts, dried powder (500 mg), was dissolved in distilled water and then centrifuged (500g, 15 min). The supernatants were transferred to micro-centrifuge tubes and stored (at À20°C). The amount of total soluble solids in supernatant was measured using gravimetric analysis which served as the basis to formulate T. arjuna concentrations.
We have selected four optimum doses of T. arjuna suspension viz., 75, 100, 150 and 200 lg/ml for lymphocyte culture in vitro and five doses viz., 50, 100, 150, 250 and 350 mg/kg body weight for in vivo experiments.
In vivo study
Albino mice 8-10 weeks old (25-35 gm in weight) were exposed to mutagen and different concentrations of Terminalia Figure 1 Showing in vivo anticarcinogenic effect of Terminalia arjuna at 16, 24, and 31 h of treatment durations against Aflatoxin B1 genotoxicity in Albino mice bone marrow cell (significant at P < 0.05 level). extract preparation by appropriate routes (intra peritoneal i.e., I.P injection) and were sacrificed at sequential intervals of 16, 24 , and 32 h of stipulated treatment time. Animals were treated with each test substance as mentioned above. Further processes of slide preparation, the cells and chromosomal aberration analyses are adopted from an earlier published work [15] . The reduction factors due to test chemical treatments were calculated using the formula published earlier [16] . The work was carried out following the guideline of institutional ethics committee and in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for humans and animals.
In vitro lymphocyte culture method
The chromosomal changes (numerical and structural) were utilized for the investigation of the genotoxic as well as antigenotoxic potentiality of test chemicals. The parameters studied included chromosomal aberrations (CA), sister chromatid exchanges (SCEs) and cell growth kinetics (RI) both in the presence and in the absence of exogenous metabolic activation system. The in vitro culture methods, preparation of S 9 (microsomal fraction), media preparation and analyses of chromosomal aberrations, sister chromatid exchanges, cell cycle kinetics and statistical analysis were followed as per the methodology published earlier [15, 16] . . 1 ).
Results
In vivo effect of Terminalia arjuna extracts
The gross effects on the total frequencies of aberrations per thousand cells were 357, 279, 239, 183 and 149 due to five different doses of Terminalia extracts along with AFB 1 , against 429 aberrations of Aflatoxin B 1 when given alone. The normal control value was 40 for only Terminalia extract treatment without AFB 1 added. Most of the cells have one or two aberrations per cell. When the treatment durations were increased to 24 h, the effects followed similar trends, but with increasing values. The observed values were 15.7%, 14.0%, 11.4%, 10.5% and 9.2% respectively at five concentrations of Terminalia extracts given with AFB 1 against only 19.7% aberrant cells for Aflatoxin B 1 alone, whereas normal value was 3.4 for Terminalia extracts as shown in Fig. 1 .
The effect of Terminalia extracts in reducing the frequency of aberrations per cell and the total number of aberrations were statistically significant at <0.05 level. The total aberrations per thousand cells were 329, 272, 205, 163 and 142 for Terminalia extracts given with AFB 1 against 429 with Aflatoxin B 1 alone. Further, the animals were exposed to 32 h; the increase in aberrant cells observed was 15.5%, 14.5%, 13.4%, 11.0% and 8.9% for five increasing doses of Terminalia extracts against the normal control value which was 3.1%. The effects on reduction in aberrant cells were 21.32%, 26.40%, 31.98%, 44.16% and 54.82% respectively, which were statistically significant. It shows almost a dose-dependent relationship as shown in Tables 1 and 2 and Fig. 1. 
In vitro effect of Terminalia arjuna extracts
The role of T. arjuna extracts in reducing metaphase aberrations due to Aflatoxin B 1 is quite significant, varying from untreated positive control values (23.49%, 42.47%, and 59.65%) to treated ones (12.32%, 28.00%, and 36.88%) at the highest dose (E 4 ) for the three different durations viz., 24, 48 and 72 h. There was no change in basal clastogeny of the cell (2.75% and 3.58%) by T. arjuna extracts. The effects showed Table 4 In vitro analysis of sister chromatid exchanges (SCE) after treatment with Aflatoxin B 1 along with Terminalia arjuna extract, in the absence as well as presence of S 9 mix.
Treatment
Duration (h) Metabolic activation Metaphase scanned Total SCE Range SCE/cell ± SE a linear dose-response relationship. The effective maximum reductions in the clastogeny were 47.55%, 34.07% and 38.17% percent at three different durations respectively as shown in Table 3 Fig. 2 . Similarly in the presence of S 9 metabolic activation system, the same values were reduced to 49.93%, 33.67% and 35.34% (Fig. 3) . The effect on sister chromatid exchange counts was similarly reduced; however the experiments were conducted only for 48 h for all treatments including control. The 50 metaphases were scored for each treatment along with S 9 treatment as shown in Table 4 The replication index calculated showed a significant elevation of R.I in comparison to aflatoxin B 1 treatment. Here, the dose-effect relationship was linear as shown in Table 5 .
Discussion
Due to global environmental pollution and modern life style, there has been an increase in the rate of mutations leading to cancer. The ways to neutralize the effect of such mutagenic and carcinogenic agents is to identify the substances that can antagonize their effects. Plants are the promising sources of antimutagens found in them as secondary metabolites [17] . In earlier studies, we have shown the antimutagenic and anticarcinogenic potential of vitamins, carotenoids and extracts of Caesalpinia bonducella and Agaricus bisporus [15, 16, 18, 19] . These antimutagenic agents may help in strengthening the cell defense mechanism against environmental carcinogens. It has been suggested earlier that halving the rate of mutations would delay the onset of most cancers and might be adequate in the lifetime of many individuals [20] . T. arjuna is a well known medicinal plant, particularly its bark is extensively used in ayurvedic medicines. Keeping in mind the medicinal importance of T. arjuna, the present study aimed at observing the anticarcinogenic and antimutagenic potential of this medicinal plant with the potential to combat a number of mutagens and carcinogens.
Tannins and flavones in the leaves, barks and stems of T. arjuna were reported to be responsible mainly for anticancer activity [21] . Antimutagenic assay of ethyl ether extracts of arjuna bark carried out by using the 'comet' assay and micronuclei test revealed that extracts are effective in reducing the DNA damage induced by 4NQO [22] . Increased levels of plasma and the liver glycolytic enzymes and decreased level of glucose-6-phosphatase were reverted to normal by depleting the energy metabolism and inhibiting the cancer growth accounting for its anticancer potential [23] . Luteolin, a flavone isolated from the butanol fraction of T. arjuna was found to be effective in inhibiting a series of solid tumors (Renal A-549, ovary SK-OV-3, Brain SF-295, etc.). It also acted as an antitumor promoter and had antimutagenic properties [24] . It was also reported the efficacy of T. arjuna in inhibiting the proliferation of the human hepatoma cell lines (HepG2) as well as a potent inhibitor of CYP isoform that prevents the conversion of cyclophosphamide or aflatoxin B 1 to its genotoxic metabolite [25, 26] . Its antimutagenic effect may be due to the direct protection of DNA from electrophilic mutagens or their metabolites or by formation of adducts that may result in the prevention of genotoxic damage [27] . The effect of bark extract of T. arjuna was studied on the alteration of adriamycin (ADR)-induced micronuclei formation in cultured human peripheral blood lymphocytes. These results demonstrate that extract of T. arjuna protects DNA against ADR-induced damage [28] that was parallel to our finding in vitro using replication index parameter.
Conclusion
The role of T. arjuna extracts in reducing metaphase aberrations due to aflatoxin B 1 is quite significant, the reduction varying from 23.49%, 42.47%, and 59.65% down to 12.32%, 28.00%, and 36.88% respectively at the highest dose (E 4 ) for the three different durations viz., 24, 48 and 72 h. Similarly the number of sister chromatid exchanges got reduced from higher level of 15.00 ± 1.40 per cell to 7.70 ± 0.50 per cell with S 9 mix at 48 h of treatment. The replication index was enhanced from 1.33 to 1.55 in vitro. Similar trends were noticed in the in vivo experiments i.e., effective reductions in clastogeny ranging from 15.22% to 54.82% from the mutagen treated positive control and the total frequencies in aberrant cells got reduced from 429 due to AFB1 to 141 due to 5th concentration of Terminalia extracts at 32 h of exposure. The ameliorating potential of Terminalia extracts was dose and time dependant.
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